Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue
- PMID: 3244662
- DOI: 10.1023/a:1015977526617
Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue
Abstract
A relatively nonhygroscopic crystalline form of the glycopeptide, N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine (I), containing approximately one molecule of water was prepared from amorphous material. The crystalline material, consisting of a mixture of the alpha and beta anomers, exhibited better physical and chemical stability than the lyophilized amorphous material. The alpha/beta-anomer ratios of I in both the crystalline and the amorphous state were approximately equal but different from that in solution.
Similar articles
-
Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.Pharm Res. 1988 Aug;5(8):528-32. doi: 10.1023/a:1015929610687. Pharm Res. 1988. PMID: 3244663
-
Physico-chemical properties of muroctasin.Arzneimittelforschung. 1988 Jul;38(7A):953-9. Arzneimittelforschung. 1988. PMID: 3190802
-
Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.Pharm Res. 1989 Sep;6(9):748-52. doi: 10.1023/a:1015915212195. Pharm Res. 1989. PMID: 2813271
-
New developments in the field of synthetic muramyl peptides, especially as adjuvants for synthetic vaccines.Drugs Exp Clin Res. 1986;12(6-7):429-40. Drugs Exp Clin Res. 1986. PMID: 3527628 Review.
-
Past, present and future of the synthetic immunoadjuvant MDP and its analogs.Biochem Pharmacol. 1978;27(18):2183-6. doi: 10.1016/0006-2952(78)90074-6. Biochem Pharmacol. 1978. PMID: 365182 Review. No abstract available.
Cited by
-
Solid-state phase transitions initiated by water vapor sorption of crystalline L-660,711, a leukotriene D4 receptor antagonist.Pharm Res. 1991 Feb;8(2):148-55. doi: 10.1023/a:1015871415925. Pharm Res. 1991. PMID: 2023861
-
Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution.Pharm Res. 1988 Aug;5(8):528-32. doi: 10.1023/a:1015929610687. Pharm Res. 1988. PMID: 3244663
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources